Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ieramilimab +/- Spartalizumab in Advanced Malignancies
NCT02460224Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of ieramilimab in solid tumor, non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
ieramilimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)mesothelioma
Beyond the preview
Go deeper on NCT02460224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460224.